Development and characterization of immuno-nanocarriers targeting the cancer stem cell marker AC133

International Journal of Pharmaceutics

Volumn 423, Issue 1, 2012, Pages 93-101

  Bourseau Guilmain, E ^a,b   Bejaud J ^a,b   Griveau, A ^a,b   Lautram, N ^a,b   Hindre F ^a,b   Weyland, M ^a,b   Benoit, J P ^a,b   Garcion, E ^a,b  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b LUNAM Universite   (France)

Author keywords

Antibody; Caco 2; CD133; Lipid nanocapsules; Nanoparticles; Specific targeting; Stem cells; Targeted therapies

Indexed keywords

CD133 ANTIGEN; EPITOPE; ETHYLENE GLYCOL; IMMUNOGLOBULIN G1; LIPID; MALEIMIDE; MONOCLONAL ANTIBODY; NANOCAPSULE; NANOCARRIER;

CANCER STEM CELL; CELL STRAIN CACO 2; COLORIMETRY; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; NANOMEDICINE; PHENOTYPE; PRIORITY JOURNAL; PURIFICATION;

ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS, CD; ANTIGENS, NEOPLASM; CACO-2 CELLS; CELL ADHESION; CELL MEMBRANE; CYTOPLASM; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; GLYCOPROTEINS; HUMANS; IMIDOESTERS; LECITHINS; MALEIMIDES; NANOCAPSULES; NANOCONJUGATES; PARTICLE SIZE; PEPTIDES; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; RNA, SMALL INTERFERING; STATIC ELECTRICITY; STEARIC ACIDS; SULFHYDRYL COMPOUNDS; SURFACE PROPERTIES; TRIGLYCERIDES;

EID: 84855778719     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.06.001     Document Type: Conference Paper

References (48)

1. E. Allard, F. Hindre, C. Passirani, L. Lemaire, N. Lepareur, N. Noiret, P. Menei, and J.P. Benoit 188Re-loaded lipid nanocapsules as a promising radiopharmaceutical carrier for internal radiotherapy of malignant gliomas Eur. J. Nucl. Med. Mol. Imaging 35 2008 1838 1846
2. J.M. Angelastro, and M.W. Lame Overexpression of CD133 promotes drug resistance in C6 glioma cells Mol. Cancer Res. 8 2010 1105 1115
3. S. Bao, Q. Wu, R.E. McLendon, Y. Hao, Q. Shi, A.B. Hjelmeland, M.W. Dewhirst, D.D. Bigner, and J.N. Rich Glioma stem cells promote radioresistance by preferential activation of the DNA damage response Nature 444 2006 756 760 (Pubitemid 44949604)
4. E.E. Bar, A. Chaudhry, A. Lin, X. Fan, K. Schreck, W. Matsui, S. Piccirillo, A.L. Vescovi, F. DiMeco, and A. Olivi Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma Stem Cells 25 2007 2524 2533 (Pubitemid 47582744)
5. A. Beduneau, P. Saulnier, F. Hindre, A. Clavreul, J.C. Leroux, and J.P. Benoit Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab' fragments Biomaterials 28 2007 4978 4990 (Pubitemid 47371148)
6. R.J. Boado, Y. Zhang, Y. Wang, and W.M. Pardridge GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier Biotechnol. Bioeng. 100 2008 387 396 (Pubitemid 351758180)
7. B. Campos, F. Wan, M. Farhadi, A. Ernst, F. Zeppernick, K.E. Tagscherer, R. Ahmadi, J. Lohr, C. Dictus, and G. Gdynia Differentiation therapy exerts antitumor effects on stem-like glioma cells Clin. Cancer Res. 16 2010 2715 2728
8. A. Casaco, G. Lopez, I. Garcia, J.A. Rodriguez, R. Fernandez, J. Figueredo, L. Torres, A. Perera, J. Batista, and R. Leyva Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma Cancer Biol. Ther. 7 2008 333 339 (Pubitemid 351847044)
9. D. Corbeil, K. Roper, A. Weigmann, and W.B. Huttner AC133 hematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family? Blood 91 1998 2625 2626 (Pubitemid 28155545)
10. B. Dehouck, L. Fenart, M.P. Dehouck, A. Pierce, G. Torpier, and R. Cecchelli A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier J. Cell Biol. 138 1997 877 889 (Pubitemid 27365049)
11. R. Dringen Metabolism and functions of glutathione in brain Prog. Neurobiol. 62 2000 649 671 (Pubitemid 30407139)
12. G. Ferrandina, M. Petrillo, G. Bonanno, and G. Scambia Targeting CD133 antigen in cancer Expert Opin. Ther. Targets 13 2009 823 837
13. E. Friedmann Spectrophotometric investigation of the interaction of glutathione with maleimide and n-ethylmaleimide Biochim. Biophys. Acta 9 1952 65 75
14. E. Garcion, A. Faissner, and C. ffrench-Constant Knockout mice reveal a contribution of the extracellular matrix molecule tenascin-C to neural precursor proliferation and migration Development 128 2001 2485 2496 (Pubitemid 32685090)
15. E. Garcion, A. Lamprecht, B. Heurtault, A. Paillard, A. Aubert-Pouessel, B. Denizot, P. Menei, and J.P. Benoit A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats Mol. Cancer Ther. 5 2006 1710 1722 (Pubitemid 44323239)
16. B. Heurtault, P. Saulnier, B. Pech, J.E. Proust, and J.P. Benoit A novel phase inversion-based process for the preparation of lipid nanocarriers Pharm. Res. 19 2002 875 880 (Pubitemid 34692585)
17. C. Hicks, E. Ladi, C. Lindsell, J.J. Hsieh, S.D. Hayward, A. Collazo, and G. Weinmaster A secreted Delta1-Fc fusion protein functions both as an activator and inhibitor of Notch1 signaling J. Neurosci. Res. 68 2002 655 667 (Pubitemid 34594983)
18. D. Horst, S.K. Scheel, S. Liebmann, J. Neumann, S. Maatz, T. Kirchner, and A. Jung The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer J. Pathol. 219 2009 427 434
19. J. Huwyler, D. Wu, and W.M. Pardridge Brain drug delivery of small molecules using immunoliposomes Proc. Natl. Acad. Sci. U.S.A. 93 1996 14164 14169 (Pubitemid 26424263)
20. N. Iznaga Escobar, A. Morales, and G. Nunez Micromethod for quantification of SH groups generated after reduction of monoclonal antibodies Nucl. Med. Biol. 23 1996 641 644 (Pubitemid 26295580)
21. J. Kreuter, P. Ramge, V. Petrov, S. Hamm, S.E. Gelperina, B. Engelhardt, R. Alyautdin, H. von Briesen, and D.J. Begley Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles Pharm. Res. 20 2003 409 416 (Pubitemid 36288370)
22. F. Lacoeuille, E. Garcion, J.P. Benoit, and A. Lamprecht Lipid nanocapsules for intracellular drug delivery of anticancer drugs J. Nanosci. Nanotechnol. 7 2007 4612 4617
23. K. Maruyama, T. Takizawa, T. Yuda, S.J. Kennel, L. Huang, and M. Iwatsuru Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies Biochim. Biophys. Acta 1234 1995 74 80
24. H. Miletic, S.P. Niclou, M. Johansson, and R. Bjerkvig Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms Expert Opin. Ther. Targets 13 2009 455 468
25. S. Miraglia, W. Godfrey, A.H. Yin, K. Atkins, R. Warnke, J.T. Holden, R.A. Bray, E.K. Waller, and D.W. Buck A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning Blood 90 1997 5013 5021 (Pubitemid 28007218)
26. S.R. Morris, and L.A. Carey Trastuzumab and beyond: new possibilities for the treatment of HER2-positive breast cancer Oncology (Williston Park) 20 2006 1763 1771 discussion 1771-1762, 1774-1766
27. P.F. Morrison, R.R. Lonser, and E.H. Oldfield Convective delivery of glial cell line-derived neurotrophic factor in the human putamen J. Neurosurg. 107 2007 74 83 (Pubitemid 47026475)
28. C.S. Niu, M.W. Li, Y.F. Ni, J.M. Chen, J.M. Mei, J. Li, and X.M. Fu Effect of all-trans retinoic acid on the proliferation and differentiation of brain tumor stem cells J. Exp. Clin. Cancer Res. 29 2010 113
29. J.C. Olivier, R. Huertas, H.J. Lee, F. Calon, and W.M. Pardridge Synthesis of pegylated immunonanoparticles Pharm. Res. 19 2002 1137 1143 (Pubitemid 34984997)
30. A. Paillard, F. Hindre, C. Vignes-Colombeix, J.P. Benoit, and E. Garcion The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability Biomaterials 31 2010 7542 7554
31. W.M. Pardridge, D. Wu, and T. Sakane Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration Pharm. Res. 15 1998 576 582 (Pubitemid 28214951)
32. D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, and R. Langer Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2 2007 751 760 (Pubitemid 350223348)
33. D.A. Reardon, M.R. Zalutsky, G. Akabani, R.E. Coleman, A.H. Friedman, J.E. Herndon 2nd, R.E. McLendon, C.N. Pegram, J.A. Quinn, and J.N. Rich A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost Neuro Oncol. 10 2008 182 189
34. E. Roger, F. Lagarce, E. Garcion, and J.P. Benoit Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis J. Control Release 140 2009 174 181
35. E. Roger, F. Lagarce, E. Garcion, and J.P. Benoit Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells Eur. J. Pharm. Sci. 40 2010 422 429
36. D. Schrama, R.A. Reisfeld, and J.C. Becker Antibody targeted drugs as cancer therapeutics Nat. Rev. Drug Discov. 5 2006 147 159
37. H. Schulz, J.F. Bohlius, S. Trelle, N. Skoetz, M. Reiser, T. Kober, G. Schwarzer, M. Herold, M. Dreyling, and M. Hallek Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis J. Natl. Cancer Inst. 99 2007 706 714 (Pubitemid 47078732)
38. M.A. Schwartz, C. Lechene, and D.E. Ingber Insoluble fibronectin activates the Na/H antiporter by clustering and immobilizing integrin alpha 5 beta 1, independent of cell shape Proc. Natl. Acad. Sci. U.S.A. 88 1991 7849 7853 (Pubitemid 21915252)
39. G.E. Sims, and T.J. Snape A method for the estimation of polyethylene glycol in plasma protein fractions Anal. Biochem. 107 1980 60 63 (Pubitemid 11196629)
40. L.M. Smith, A. Nesterova, M.C. Ryan, S. Duniho, M. Jonas, M. Anderson, R.F. Zabinski, M.K. Sutherland, H.P. Gerber, and K.L. Van Orden CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers Br. J. Cancer 99 2008 100 109 (Pubitemid 351920235)
41. O. Tirosh, Y. Barenholz, J. Katzhendler, and A. Priev Hydration of polyethylene glycol-grafted liposomes Biophys. J. 74 1998 1371 1379 (Pubitemid 28108545)
42. M. Todaro, M.P. Alea, A.B. Di Stefano, P. Cammareri, L. Vermeulen, F. Iovino, C. Tripodo, A. Russo, G. Gulotta, and J.P. Medema Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4 Cell Stem Cell 1 2007 389 402 (Pubitemid 47506537)
43. J.E. Visvader, and G.J. Lindeman Cancer stem cells in solid tumours: accumulating evidence and unresolved questions Nat. Rev. Cancer 8 2008 755 768
44. C.H. Wang, S.H. Chiou, C.P. Chou, Y.C. Chen, Y.J. Huang, and C.A. Peng Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody Nanomedicine 7 2011 69 79
45. M. Weyland, F. Manero, A. Paillard, D. Gree, G. Viault, D. Jarnet, P. Menei, P. Juin, I. Chourpa, and J.P. Benoit Mitochondrial targeting by use of lipid nanocapsules loaded with SV30, an analogue of the small-molecule Bcl-2 inhibitor HA14-1 J. Control Release 151 2011 74 82
46. F. Winau, O. Westphal, and R. Winau Paul Ehrlich - in search of the magic bullet Microbes Infect. 6 2004 786 789 (Pubitemid 38781191)
47. Y. Wu, and P.Y. Wu CD133 as a marker for cancer stem cells: progresses and concerns Stem Cells Dev. 18 2009 1127 1134
48. F. Zeppernick, R. Ahmadi, B. Campos, C. Dictus, B.M. Helmke, N. Becker, P. Lichter, A. Unterberg, B. Radlwimmer, and C.C. Herold-Mende Stem cell marker CD133 affects clinical outcome in glioma patients Clin. Cancer Res. 14 2008 123 129 (Pubitemid 351377986)